NCT03364725 (ELIMINATEC) is a Phase 4 clinical trial of Glecaprevir-pibrentasvir in Hepatitis C, sponsored by Id Care.

Who is sponsoring NCT03364725?

NCT03364725 is sponsored by Id Care.

What drugs are being tested in NCT03364725?

Interventions in NCT03364725: Glecaprevir-pibrentasvir.

What condition does NCT03364725 study?

NCT03364725 studies Hepatitis C, Addict Heroin.

Is NCT03364725 still recruiting?

NCT03364725 is currently status unknown. Last updated 7 December 2017.

Last reviewed 2017-12-07 · How we verify

NCT03364725: ELIMINATEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

Status unknown Phase 4 Last updated 7 December 2017

What this trial tests

Phase 4 trial testing Glecaprevir-pibrentasvir in Hepatitis C in 30 participants. Status unknown.

Timeline

15 January 2018

Primary endpoint
1 September 2018

1 March 2019

Quick facts

Lead sponsor	Id Care
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	15 January 2018
Primary completion	1 September 2018
Estimated completion	1 March 2019
Sites	1 location across United States

Drugs / interventions tested

Glecaprevir-pibrentasvir — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →
Addict Heroin — all drugs for Addict Heroin →

Sponsor

Id Care — full company profile →

Who can join

Adults 18 to 30, any sex, with Hepatitis C or Addict Heroin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Glecaprevir-pibrentasvir

Trials testing the same drug.

NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03364725 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Id Care
Last refreshed: 7 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03364725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing